Cargando…

Ulcerative Colitis: Shifting Sands

Ulcerative colitis (UC) is a chronic inflammatory bowel disease associated with considerable disease burden. We review some current misconceptions about UC in adults with the aim of optimizing care for patients. Although UC and Crohn’s disease (CD) are considered discrete diseases, distinctions betw...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Haens, Geert R. A. M., Lindsay, James O., Panaccione, Remo, Schreiber, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Current Opinion
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544716/ https://www.ncbi.nlm.nih.gov/pubmed/30827006 http://dx.doi.org/10.1007/s40268-019-0263-2

Ejemplares similares

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data
por: Danese, Silvio, et al.
Publicado: (2023)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis
por: Berends, Sophie E., et al.
Publicado: (2018)

Prognostic Value of Colonic Tissue and Blood Eosinophils in Ulcerative Colitis
por: Haasnoot, Maria L, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme
por: Sandborn, William J, et al.
Publicado: (2022)

Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index
por: Bots, Steven, et al.
Publicado: (2021)

Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review
por: Colombel, Jean-Frédéric, et al.
Publicado: (2020)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Drug Exposure and the Risk of Microscopic Colitis: A Critical Update
por: Lucendo, Alfredo J.
Publicado: (2017)

Paradigm shift of drug information centers during the COVID-19 pandemic
por: Khatiwada, Asmita Priyadarshini, et al.
Publicado: (2020)

Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients
por: Berends, Sophie E., et al.
Publicado: (2019)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Increased Proportion of Colorectal Cancer in Patients With Ulcerative Colitis Undergoing Surgery in the Netherlands
por: Heuthorst, Lianne, et al.
Publicado: (2023)

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study
por: Yarlas, Aaron, et al.
Publicado: (2018)

Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial
por: Rubin, David T., et al.
Publicado: (2016)

A Reliability Study: Strong Inter-Observer Agreement of an Expert Panel for Intestinal Ultrasound in Ulcerative Colitis
por: De Voogd, Floris, et al.
Publicado: (2021)

Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers—Do We Have Enough Evidence?
por: Dubský, Michal, et al.
Publicado: (2023)

Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study
por: Willian, Mary Kaye, et al.
Publicado: (2018)

Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions
por: Dubinsky, Marla, et al.
Publicado: (2023)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Low prevalence of Blastocystis sp. in active ulcerative colitis patients
por: Rossen, N. G., et al.
Publicado: (2015)

Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn’s Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials
por: Panaccione, Remo, et al.
Publicado: (2018)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52
por: Johnson, Travis, et al.
Publicado: (2023)

Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians
por: Rubin, David T, et al.
Publicado: (2020)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Revision of Ireland’s Cost-Effectiveness Threshold: New State-Industry Drug Pricing Deal Should Adequately Reflect Opportunity Costs
por: O’Mahony, James F.
Publicado: (2021)

Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls – a prospective cohort study
por: Reijntjes, Maud A., et al.
Publicado: (2022)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Bridging the divide: a model-data approach to Polar and Alpine microbiology
por: Bradley, James A., et al.
Publicado: (2016)

Fuel for the Work Required: A Theoretical Framework for Carbohydrate Periodization and the Glycogen Threshold Hypothesis
por: Impey, Samuel G., et al.
Publicado: (2018)

Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk
por: Rajasimhan, Suraj, et al.
Publicado: (2020)

Global position paper on cardiovascular regenerative medicine
por: Fernández-Avilés, Francisco, et al.
Publicado: (2017)

Medical consultation in ulcerative colitis: Key elements for improvement
por: González-Lama, Yago, et al.
Publicado: (2023)

Mpox and Monkeypox Virus: Special Considerations for Athletes in Contact Sports
por: Smoliga, James M.
Publicado: (2023)

Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial
por: Löwenberg, Mark, et al.
Publicado: (2023)

Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn’s Disease: Post Hoc Analyses of VISIBLE Studies
por: Sandborn, William J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26jj2tba17g4ulp0d9ucvsd4b6